Category
18 plain-language articles on compounding and compliance — the physiology, the compounds, and what the evidence actually shows.
18 articles
503A vs 503B: what "compounded" actually means
You're looking at two pharmacy websites side by side and they both have peptides for sale. One mentions 503A. The other mentions 503B. You don't know what either of those numbers means, and you don't want to be the kind of person who asks. So you squint at the fine print, look for a trust badge or a seal, and eventually just pick the one with the cleaner website.
The anti-aging clinic phenomenon — from hormone-replacement to peptide protocols
A full-page advertisement in a trade publication from 2002 shows a physician in a white coat standing next to a silver-haired couple who look ten years younger than they probably are. "Turn Back the Clock," the headline says. The American Academy of Anti-Aging Medicine — A4M — is holding its annual World Congress, the largest gathering of what it calls "longevity physicians" in the world. Thousands of physicians will attend. They will receive continuing medical education credit. They will hear presentations on growth hormone optimization, testosterone and estrogen replacement, telomere biology, dietary supplement protocols, and the emerging category of peptide interventions. They will return to their practices with a new clinical identity: anti-aging medicine. A subset of them will open dedicated clinics.
The history of compounding pharmacy — from the 1990s to the modern peptide landscape
On a Friday in September 2012, a patient in Tennessee developed what his physicians initially mistook for bacterial meningitis. By the weekend, clinicians at Vanderbilt University Medical Center were confused: the infection was not responding to antibiotics, the imaging was unusual, and the spinal fluid was not showing the bacterial pattern they expected. By the following week, they had identified the organism. It was Exserohilum rostratum, a common mold found in soil and plant matter. It had no business being in anyone's spinal cord. Tracing backward, investigators found the same fungus in patients in other states — Tennessee, Michigan, Virginia, Florida — all of whom had received epidural steroid injections for back pain in recent weeks. All of them had received the same methylprednisolone acetate preparation. All of it came from one facility in Framingham, Massachusetts: the New England Compounding Center.
Compounding pharmacy quality variation — what's actually different from one pharmacy to another
You assume a licensed pharmacy is a licensed pharmacy. The license hangs on the wall, the state board approved the operation, the pharmacist passed their boards. The peptide you're getting from a licensed compounding pharmacy in one state should be the same quality as the peptide from a licensed pharmacy in another state. That assumption is wrong, and the degree to which it's wrong is something the wellness marketing around compounded peptides almost never discusses.
What the FDA actually says about compounded peptides
You've read something online that says compounded peptides are "banned by the FDA." You've also read something that says the FDA has nothing to do with compounded medications and it's all perfectly legal. Both of those things feel partially true and you can't reconcile them into a single coherent picture. The confusion is understandable. It's also fixable — because the FDA's actual position is precise, if you read it carefully rather than reading it through the filter of whoever was alarmed or reassured enough to write about it.
FDA enforcement actions against peptide companies — what's happened and what it teaches
The warning letter arrives and the company's website goes dark. Maybe the FAQ page stays up for a few days with an explanation about "regulatory review." Maybe the domain just stops loading. Users who have been relying on that vendor for their supply find themselves scrambling, posting in forums, asking where else to go. The regulatory action that triggered it was months or years in development. For the users, it arrives as a sudden disruption. They had no warning because the vendor had no incentive to provide one.
Finding a physician who's knowledgeable about peptides
What you want isn't a second medical system running parallel to the one that has your records and knows your history. You want someone who understands peptide pharmacology and can integrate that knowledge with the rest of your care — who knows what you're taking, can monitor it intelligently, and can talk to your cardiologist or gynecologist if something unexpected comes up. That's a reasonable thing to want. It's also genuinely hard to find, and understanding why helps you search more effectively.
How to read a peptide pharmacy's certificate of analysis
You get the PDF. It's four pages long, dense with numbers and abbreviations, and somewhere on page two there's a percentage — 98.7% — next to something called "assay." You assume that's good. You don't actually know what assay means, or what number would be bad, or whether you're even reading the column that applies to your vial. So you scroll to the bottom, confirm it says "pass" a few times, and call it done.
The legal landscape for peptides — what's actually allowed
You're looking at a peptide on a supplier's website. One site calls it a research chemical and notes it's not for human consumption. Another site offers the same compound through a telehealth clinic with a prescription. A third forum thread says you can order it internationally with no issues. Three descriptions of what sounds like the same molecule, and none of them is obviously lying. The regulatory landscape for peptides is genuinely complicated, and the confusion isn't manufactured — it reflects real fragmentation across FDA jurisdiction, compounding law, drug scheduling, and enforcement priorities. Understanding the actual framework helps you distinguish between legal pathways and those that simply haven't been enforced yet.
Oral peptide delivery — the engineering breakthroughs that may transform peptide therapy
The first time most people hear they'll need to inject a peptide — weekly, subcutaneously, into the abdomen or thigh — there's a pause. Not everyone walks away. But some do, and more simply never start. The needle is a real barrier in a way that swallowing a pill isn't, and that barrier has shaped the entire history of peptide therapeutics: which drugs got developed, which patient populations were reachable, which indications were commercially viable. Insulin has required injection for a century. Most peptide drugs have followed the same path, for the same underlying reason.
The COA gaming problem — why "third-party tested" doesn't always mean what you think
When a peptide company says "third-party tested," you probably picture an independent laboratory that received a sample of the exact product you're about to buy, ran it through meaningful analytical instruments, and confirmed that what's on the label is what's in the vial — correct identity, correct concentration, acceptable purity, and, for injectables, absence of the contaminants that matter for safety. That picture is accurate for some products. It is not accurate for a significant portion of the peptide market, and the gap between the marketing claim and the actual quality practice is large enough to affect decisions.
Peptide influencer conflicts of interest — what to know about the recommendations you're reading
The podcaster has been discussing BPC-157 for forty minutes. He explains the mechanism clearly — gut lining repair, tendon healing, angiogenesis — and his enthusiasm is real, or performs well as real. Near the end he mentions he's been using it for three months and his knee has never felt better. He gives a code. Ten percent off at the vendor he uses. He doesn't mention that the vendor is paying him a percentage of every sale that code generates. He doesn't mention that when he signed the affiliate deal six months ago, he agreed to produce a certain number of favorable mentions per quarter.
Peptide protocol troubleshooting — when something isn't working
Six weeks in and nothing has changed. Or something changed but not what you expected, and now you're trying to decide whether to add a compound, switch compounds, increase the dose, or conclude that peptides just don't work for you. Before any of those moves, there's a prior question that most people skip: is the protocol actually not working, or are you assessing it incorrectly?
The regulatory future for peptides — what's coming and what it means
The access to compounded peptides that many people take for granted right now was not designed to be permanent. It exists because of a specific regulatory structure — the compounding pharmacy framework — that was built for specific purposes, and the conditions that made that framework hospitable to the current range of compounded peptides are actively shifting. The question isn't whether the regulatory environment for peptides will change. It's how fast, in what direction, and what a thoughtful response looks like for the people who are using or considering using compounded peptides now.
Peptide research fraud and questionable studies — what to know about the integrity of the literature
In 2015, the Open Science Collaboration published the results of an effort to reproduce 100 studies from three top psychology journals. The original papers had all been published in peer-reviewed outlets, passed editorial and reviewer scrutiny, and entered the scientific record as established findings. The reproducibility project, which used the original study authors' materials and methods wherever possible, found that only 36 of the 100 studies replicated with statistical significance. The scientific community absorbed this finding with varying degrees of alarm, but the direction of the conclusion was not disputed: a substantial fraction of published research, even in prominent journals, does not reproduce when someone else tries it. This is not a peripheral problem in science. It is central to how the enterprise actually works, which is to say imperfectly, with self-correction mechanisms that operate more slowly than publication mechanisms and with significant variation in how rigorous any given piece of research actually is.
What "research peptide" labels really mean — and why they matter for what you're buying
You're looking at two product pages side by side. Both sell the same compound — same name, similar molecular descriptions, roughly similar concentrations. One is priced at forty dollars. The other, from a licensed compounding pharmacy, requires a prescription and costs four times that. Both are described as "BPC-157" or "Tirzepatide" or whatever you went looking for. The cheaper one has a small line of text near the bottom of the page, easy to miss in the usual scan: "For research purposes only. Not for human consumption. Not intended for diagnostic or therapeutic use." You wonder if that language is just legal boilerplate, something every company puts up to cover themselves. It isn't.
The supplement pile that isn't quite helping — when you've stacked too much
The pill organizer is full. Not metaphorically — it takes a few minutes to fill it each week, and if you forget which compartment you filled you have to look at each one because you've lost track of the sequence. There's a multivitamin in there, because baseline seems sensible. Omega-3 because cardiovascular and inflammation. Magnesium because sleep, and also stress, and also because everyone seems to be taking magnesium now. Vitamin D. B-complex. Ashwagandha for cortisol, which you read about two years ago and kept going. An NAD precursor because mitochondria and aging. Collagen because joints and skin. Lion's mane because cognitive support. Some days a berberine capsule because metabolic health. The total lands somewhere between fifteen and twenty depending on the week and what you remembered to reorder. You've spent a meaningful amount of money on all of it. The honest answer to whether any of it is working is: you're not sure. If you stopped everything tomorrow, you don't know what would happen, and that uncertainty has become a reason not to stop. The doctor you mentioned it to said "most of those probably aren't doing anything," which is technically useful feedback but arrived without any guidance on which ones those were or what to do about it.
Why peptide companies disappear — and what that tells you about the market
You found a supplier two or three years ago. The products seemed reliable, the customer service was responsive, the pricing was reasonable. You built a routine around them. Then one day you go to reorder and the site resolves to a parking page. The email address returns undeliverable. The Instagram account that used to post compound breakdowns and founder updates has been deleted or gone silent. If you search the company name, you find nothing recent — maybe a thread on a forum where several other people are asking the same question. They're gone.